#Denmark #Copenhagen #HERVolution #HERV-K cancer #tumor vaccine

Groundbreaking Findings from HERVolution

HERVolution Therapeutics ApS has made a significant stride in the fight against cancer with its recent announcement revealing promising data on human endogenous retrovirus K (HERV-K). The biotechnology company, renowned for pioneering immunotherapies targeting HERVs for oncology, metabolic diseases, and cellular senescence, published peer-reviewed study findings emphasizing HERV-K's potential as an effective tumor antigen in the treatment of non-small cell lung cancer (NSCLC).

Study Insights

The pivotal study, aptly titled "Endogenous Retrovirus-Targeted Immunotherapy for Non-Small Cell Lung Cancer Supported by Cellular HERV-K Expression, Dependency and Efficacy of ERV Therapy in a Murine Model," has been made open access in the International Journal of Molecular Sciences. This comprehensive research focuses on examining 207 biopsy samples from patients with advanced NSCLC, where researchers successfully identified HERV-K Gag and envelope antigen-coding sequences in all analyzed tumors.

Implications of Genetic Redundancy

This extensive analysis revealed that every tumor expressed multiple HERV-K sequences, indicating a genetic redundancy that may prove critical for a vaccine strategy. Such redundancy minimizes the risk that cancer cells can evade an immune response by silencing individual HERV-K sequences. Unlike personalized mRNA vaccines that target unique mutations specific to individual patients, HERV-K antigens can be uniformly engineered, making it feasible to create an 'off-the-shelf' cancer vaccine applicable to all patients with HERV-K expressing tumors.

Dependency on HERV-K in Lung Cancer

The dependency of lung cancer cell lines on HERV-K was strikingly highlighted during the study. When researchers conducted knockdown experiments on five NSCLC cell lines, they discovered that reducing HERV-K levels significantly hindered cancer cell proliferation and survival. Though further validation is necessary to solidify these findings, they suggest a crucial role for HERV-K in the survival of these tumors.

Moreover, analyzing the response of HERV-K proteins to inflammatory cytokines and chemotherapeutic agents revealed that these proteins not only survived but sometimes increased in levels when exposed to such pressures. This observation may contribute valuable insights into understanding tumor behavior and therapeutic strategies moving forward.

Preclinical Successes and Future Directions

In a compelling murine tumor model, immunizations against a surrogate antigen for HERV showed promising protective effects against tumors, with some subjects experiencing complete tumor regression when combined with anti-PD-L1 treatments. While it’s essential to approach these results with caution, as they are preclinical, they demonstrate the robust potential for HERV-K-targeted immunotherapies.

As HERVolution prepares for its first-in-human study of HTX-IPT001, an advanced therapeutic product designed to deliver engineered HERV-K antigens, the ramifications of this research extend far beyond lung cancer. The company also plans to explore applications in metabolic diseases and senescence, aiming for studies to commence in 2027.

Conclusion

The research led by HERVolution, in conjunction with the University of Copenhagen and other institutions, paints a promising picture for utilizing HERV-K in cancer vaccine development. The ability to harness common immunogenic pathways across diverse populations represents not only a technological breakthrough but also a potential game-changer in terms of accessibility and efficacy in cancer treatment. As the scientific community assesses these findings, the validation of HERV-K as a universal target for treating various cancers may soon revolutionize oncology therapeutics.